KAJIAN PUSTAKA: EKSPLORASI DAMPAK KLINIS PENGGUNAAN BENZODIAZEPIN PADA PASIEN SKIZOFRENIA
Sari
Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, and cognitive symptoms. Benzodiazepine are frequently prescribed as adjunctive therapy to antipsychotics. However, theit clinical impact, in terms of both efficacy and safety has yet to comprehensively evaluated. This study aimed to explore the clinical impact of benzodiazepine use in schizophrenia patients, the domains of therapeutic efficacy and safety. This research use a literature review method by searching Google Scholar, Sciencedirect, MDPI, Semantic Scholar, and Pubmedm published between 2016-2026. Inclusion criteria include Indonesia or English language, original research addressing the clinical impact of benzodiazepine. Of 1.497 article identified, 13 met the criteria and were analyzed comprehensively. These 13 studies demonstrated that benzodiazepine particulary diazepam and lorazepam were effective as adjunctive therapy in managing acute agitation, anxiety, sleep disturbances, and extrapyramidal side effect. From a safety, however long term use exceeding six months was associated with cognitive and global function decline, increased risk of dependence, withdrawal syndrome, higher rehospitalization rates, and elevated mortality. Elderly patient exhibited greater vulnerability due to age related pharmacokinetics changes. These findings indicate that benzodiazepines are beneficial as short term adjunctive therapy during the acute phase of schizophrenia, while long term use significant clinical risk, underscoring the need for careful risk benefit evaluation and monitoring, particulary among elderly patients.
Kata Kunci
Teks Lengkap:
PDFReferensi
Aburamadan, H. A. R. (2021). Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital , United Arab Emirates. 45–51. https://doi.org/10.4103/japtr.JAPTR
Achour, V., Faugere, M., Maakaron, E., Gavat, J., Fond, G., Lançon, C., & Korchia, T. (2025). Benzodiazepine use and multidimensional health burden in severe psychiatric disorders: Impaired quality of life, metabolic comorbidities, and adverse effects in a large cross-sectional study. European Psychiatry, 68(1). https://doi.org /10.1192/j.eurpsy.2025.10098
Baandrup, L. (2020). Polypharmacy in schizophrenia. 183(December 2019), 183–192. https://doi.org/ 10.1111/bcpt.13384
Brodeur, S., Chiu, Y. M., Courteau, J., Dorais, M., Oliver, D., Stip, E., Fleury, M. J., Roy, M. A., Vanasse, A., Lesage, A., & Leclerc, J. (2024). Medication Exposure and Mortality in Patients with Schizophrenia. JAMA Network Open, 7(11), 1–13. https://doi.org/10.1001/jamanetworkopen.2024.47137
Chang, Y., Xie, X., Liu, Y., Liu, M., & Zhang, H. (2024). Biomedicine & Pharmacotherapy Exploring clinical applications and long-term effectiveness of benzodiazepines : An integrated perspective on mechanisms , imaging , and personalized medicine. Biomedicine & Pharmacotherapy, 173(November 2023), 116329. https://doi.org /10.1016/j.biopha.2024.116329
Correll, C. U., Martin, A., Patel, C., Benson, C., Goulding, R., Kern-Sliwa, J., Joshi, K., Schiller, E., & Kim, E. (2022). Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia, 8(1), 1–10. https://doi.org/10.1038/s41537-021-00192-x
Cvetka Baˇcar Bole. (2023). Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. https://doi.org/https:// doi.org/10.3390/medicina59020284
de la Iglesia-Larrad, J. I., Barral, C., Casado-Espada, N. M., de Alarcón, R., Maciá-Casas, A., Vicente Hernandez, B., & Roncero, C. (2020). Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry Research, 284, 112660. https://doi.org/https://doi.org/10.1016/j.psychres.2019.112660
Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., & Leucht, S. (2012). Benzodiazepines for schizophrenia. The Cochrane Database of Systematic Reviews, 11(11), CD006391. https://doi.org/10.1002/14651858.CD006391.pub2
Fathurrahman, M. R. (2025). Perempuan 65 Tahun dengan Gangguan Skizoafektif Very Late Onset dan Benzodiazepine Withdrawal. Cermin Dunia Kedokteran, 52(1), 32–36.
Fond, G., Berna, F., Boyer, L., Godin, O., Brunel, L., Andrianarisoa, M., Aouizerate, B., Capdevielle, D., Chereau, I., Danion, J. M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Le Gloahec, T., Llorca, P. M., Mallet, J., Misdrahi, D., Rey, R., … group, T. F.-S. (FondaMental A. C. of E. for S. (2018). Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. European Archives of Psychiatry and Clinical Neuroscience, 268(1), 17–26. https://doi.org /10.1007/ s00406-017-0787-9
Fontanella, C., Campo, J., Phillips, G., Steelesmith, D., Sweeney, H., Tam, K. K., Lehrer, D., Klein, R., & Hurst, M. (2016). Benzodiazepine Use and Risk of Mortality Among Patients With Schizophrenia: A Retrospective Longitudinal Study. The Journal of Clinical Psychiatry, 77, 661–667. https://doi.org/10.4088/JCP.15m10271
Gronich, N. (2024). Central Nervous System Medications: Pharma cokinetic and Pharmaco dynamic Considerations for Older Adults. Drugs & Aging, 41(6), 507–519. https://doi.org /10.1007/ s40266-024-01117-w
Haines, S. T., Kliethermes, M. A., & Sorensen, T. D. (2025). DiPiro’s Pharmacotherapy : A Patho physiologic Approach, 13th edition. McGraw Hill.
Huang, C. L.-C., Hwang, T.-J., Chen, Y.-H., Huang, G.-H., Hsieh, M. H., Chen, H.-H., & Hwu, H.-G. (2016). Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. Journal of the Formosan Medical Association = Taiwan Yi Zhi, 114(5), 438–445. https://doi.org /10.1016/j.jfma.2015.01.018
Jeyagurunathan, A., Lau, J. H., Abdin, E., Shafie, S., Chang, S., Samari, E., Cetty, L., Wei, K.-C., Mok, Y. M., Tang, C., Verma, S., Chong, S. A., & Subramaniam, M. (2021). Aggression Amongst Outpatients With Schizophrenia and Related Psychoses in a Tertiary Mental Health Institution. Frontiers in Psychiatry, 12, 777388. https://doi. org/10.3389/fpsyt.2021.777388
Jia Ru, Yeh, L.-L., Lin, J.-Y., & Pan, Y.-J. (2024). Medication Dosage Impact on Mortality in Old-Age Individuals with Schizophrenia: A National Cohort Study. Pharmaceuticals, 17(1). https://doi.org/10.3390 /ph17010078
Jusuf, H., Ramadhani, F. N., Ramadani, D., & Papeo, P. (2024). Gambaran Penggunaan Obat Antipsikotik pada Pasien Skizofrenia di Puskesmas Kota Gorontalo. 6, 20–33.
Karsa, N. S. (2023). Efektivitas Risperidone dan Diazepam pada Pasien Skizofrenia dengan Keadaan Agitasi. Wal’afiat Hospital Journal, 04(02), 117–127. https://whj. umi.ac.id/index.php/whj/issue/archive%0AEfektivitas
Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., & Hong, S. H. (2020). The American psychiatric association practice guideline for the treatment of patients with schizophrenia. In American Journal of Psychiatry (Vol. 177, Issue 9). https://doi.org /10.1176/appi.ajp.2020.177901
Kverashvili, Malik, E., Shelef, & Stryjer. (2024). Comparing IM Lorazepam and IM Clothiapine for Agitated Psychosis in Hospitalized Patients. In European Psychiatry (Vol. 67, Issue Suppl 1, pp. S331-2). https://doi.org/10.1192/j.eurpsy.2024.686
Lin, J.-Y., Yeh, L.-L., & Pan, Y.-J. (2023). Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study. Psychological Medicine, 53(12), 5528–5537. https://doi.org/DOI: 10.1017/S0033291722002732
Liu, L., Jia, L., Jian, P., Zhou, Y., Zhou, J., & Wu, F. (2020). The Effects of Benzodiazepine Use and Abuse on Cognition in the Elders : A Systematic Review and Meta-Analysis of Comparative Studies. 11(September). https://doi.org/10.3389/fpsyt.2020.00755
Livingston, N. R., Kiemes, A., Devenyi, G. A., Knight, S., Lukow, P. B., Jelen, L. A., Reilly, T., Dima, A., Nettis, M. A., Casetta, C., Agyekum, T., Zelaya, F., Spencer, T., De Micheli, A., Fusar-Poli, P., Grace, A. A., Williams, S. C. R., McGuire, P., Egerton, A., … Modinos, G. (2024). Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.Neuropsychopharmacology, 49(9), 1448–1458. https://doi. org/10.1038/s41386-024-01864-9
Lorenz-Guertin, J. M., Povysheva, N., Chapman, C. A., MacDonald, M. L., Fazzari, M., Nigam, A., Nuwer, J. L., Das, S., Brady, M. L., Vajn, K., Bambino, M. J., Weintraub, S. T., Johnson, J. W., & Jacob, T. C. (2023). Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiology of Disease, 185, 106248.https://doi.org/10.1016/j.nbd.2023.106248
Maria, L. S., Bartz-johannesen, C. A., Kroken, R. A., Krogenes, M. L., Mehlum, L., & Johnsen, E. (2022). Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia. Journal of Clinical Psychopharmacology, 42(1), https://doi.org/10.1097/JCP.0000000000001497
Mashaw, S. A., Anwar, A. I., Vu, J. N., Thomassen, A. S., Beesley, M. L., Shekoohi, S., & Kaye, A. D. (2025). Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder. Healthcare (Switzerland), 13(8), 1–14. https://doi.org/10.3390/healthcare13080932
Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P., Chele, G., & Szalontay, A. S. (2023). Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Anti psychotics—An Observational Study. Brain Sciences, 13(2). https ://doi.org/10.3390/brainsci13020173
Noel, C., & Maclay, C. (2025). Benzodiazepine use in schizophrenia: A review of the literature. The Mental Health Clinician, 15(6), 315–322. https: //doi.org/10.9740/mhc.2025.12.315
Peritogiannis, V. (2016). Long‑term Benzodiazepine Treatment in Patients with Psychotic Disorders Attending a Mental Health Service in Rural Greece. 26–30. https://doi.org/10.4103/0976-3147.196447
Putri, I. A., & Maharani, B. F. (2022). Skizofrenia : Suatu Studi Literatur. Journal of Public Health and Medical Studies, 1(1), 1–12.
Ratna sofa, Y., Noerhidajati, E., Woroasih, S., & Intan Tri Hardini. (2024). Risk Factors of Agitation Among Schizophrenia Patients in Dr. Amino Gondohutomo Semarang Regional Psychiatric Hospital: A Cross-Sectional Study. Jurnal Psikiatri Surabaya, 13(2), 162–169. https://doi.org/10.20473/jps.v13i2.48694
Rocca, P., Brasso, C., Montemagni, C., Bellino, S., Rossi, A., Bertolino, A., Gibertoni, D., Aguglia, E., Amore, M., Andriola, I., Bellomo, A., Bucci, P., Buzzanca, A., Carpiniello, B., Cuomo, A., Dell’Osso, L., Favaro, A., Giordano, G. M., Marchesi, C., … Ribolsi, M. (2021). Accuracy of self-assessment of real-life functioning in schizophrenia. Npj Schizophrenia, 7(1).https://doi.org/10.1038/s41537-021-00140-9
Rosas-Vidal, L. (2025). Alprazolam induces anterograde amnesia for contextual fear memory and alters dorsoventral hippocampal neuronal ensembles in female mice. Scientific Reports, 1(2), 1–15. https://doi.org /https://doi.org/10.1038/s41598-025-07380-0
Saparia, P., Patel, A., Shah, H., Solanki, K., Patel, A., & Sahayata, M. (2022). Schizophrenia: A Systematic Review. Journal Clinical and Experimental Psychology, 2022(7), https://doi.org/10.1111/j.1600-0447.2005.00687.
Savić, B., Jerotić, S., Ristić, I., Zebić, M., Jovanović, N., Russo, M., & Marić, N. P. (2021). Long-Term Benzodiazepine Prescription During Maintenance Therapy of Individuals With Psychosis Spectrum Disorders-Associations With Cognition and Global Functioning. Clinical Neuropharmacology, 44(3), 89–93. https://doi.org/10.1097/WNF.0000000000000442
Schoonover, K. E., Dienel, S. J., Holly Bazmi, H., Enwright, J. F. 3rd, & Lewis, D. A. (2024). Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 49(7), 1183–1192. https://doi.org/ 10.1038/s41386-024-01854-x
Schuster, J., Hoertel, N., Gunten, A. Von, Seigneurie, A., Limosin, F., & Study, C. S. A. (2020). Benzodiazepine use among older adults with schizophrenia spectrum disorder : prevalence and associated factors in a multicenter study. International Psychogeriatrics, 32(4), 441–451. https://doi.org/10.1017/S1041610219000358
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025). Long-term neurological consequences following benzodiazepine exposure: A scoping review. PLOS ONE, 20(8), e0330277.https://doi.org/10.1371/journal.pone.0330277
Solmi, M., Seitidis, G., Mavridis, D., Correll, C. U., Dragioti, E., Guimond, S., Tuominen, L., Dargél, A., Carvalho, A. F., Fornaro, M., Maes, M., Monaco, F., Song, M., Il Shin, J., & Cortese, S. (2023). Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry, 28(12), 5319–5327. https://doi.org/10.1038/s41380-023-02138-4
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., Tan, Z., Wall, M. M., Mathai, C., & Olfson, M. (2019). Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. 76(5), 508–515. https://doi.org/ 10.1001/jamapsychiatry.2018.4489
Takeuchi, H., Takekita, Y., Hori, H., Oya, K., Miura, I., Hashimoto, N., & Yasui-Furukori, N. (2021). Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacologytreatment algorithms. Human Psycho pharmacology, 36(6), e2804. https://doi.org/10.1002/hup.2804
Tau, M. A., Moosa, M. Y. H., & Jeenah, F. Y. (2024). Long-term benzo diazepine prescriptions in community psychiatry clinics. South African Journal of Psychiatry, 30, 4–11. https://doi.org /10.4102/sa jpsychiatry.v30i0.2181
Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. American Journal of Psychiatry, 173(6), 600–606. https://doi.org/10.1176/appi.ajp.2015.15050618
Włodarczyk, A., Szarmach, J., Cubała, W. J., & Wiglusz, M. S. (2017). Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. Psychiatria Danubina, 29(Suppl 3), 345–348.
Zaman, H., Sampson, S., Beck, A., Sharma, T., Clay, F., Spyridi, S., Zhao, S., & Gillies, D. (2018). Benzodiazepines for psychosis-induced aggression or agitation. Schizophrenia Bulletin, 44(5), 966–969. https://doi.org /10.1093/ schbul/sby056
Zaric Kontic, M., Dragic, M., Martinovic, J., Mihajlovic, K., Brkic, Z., Mitrovic, N., & Grkovic, I. (2023). Prolonged Alprazolam Treatment Alters Components of Glutamatergic Neurotransmission in the Hippocampus of Male Wistar Rats—The Neuroadaptive Changes following Long-Term Benzodiazepine (Mis)Use. Pharmaceuticals, 16(3). https://doi.org/10.3390/ph16030331
DOI: https://doi.org/10.33024/jfm.v9i2.27475
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.